13th September 2021 Product update: rapidvirology staff writer
Indonesia Gives Approval to Homegrown Low-Cost Saliva-Based Rapid COVID-19 Test
Achiko is pleased to announce that the Ministry of Health of the Republic of Indonesia has granted product and registration approval for its proprietary low-cost, rapid COVID-19 diagnostic test, AptameX™, alongside its sister digital passporting service, Teman Sehat™ (“Health Buddy”). Achiko’s 50%-subsidiary, PT Achiko Medika Indonesia, and PT Indofarma TBK (“Indofarma”) have entered into an agreement to manufacture AptameX™ and have received product registration approval in Indonesia.
The approval opens the door to the rapid scale-up of production and sale of Achiko’s AptameX™ test kits in Indonesia.
Available at an affordable price, AptameX™ provides millions of Indonesian residents with access to accurate diagnostic testing for COVID-19, enabling the country to more effectively control and contain the pandemic. Indonesia passed 50,000 daily COVID-19 cases in mid-July, amid the spread of the Delta variant in Southeast Asia.
COVID-19 poses a challenge to traditional testing methods, as low viral loads evade most rapid tests, calling for a new paradigm. AptameX™ uses proprietary, novel chemistry matching the speed of lateral flow rapid tests while improving on sensitivity. At a significantly lower price point than other tests, it also offers a better user experience.
Those that test positive are alerted promptly through the Teman Sehat™ digital passport service and asked to follow local guidelines on isolation and quarantine. Its affordability, scalability, and superior performance make it an ideal tool in Indonesia’s fight against COVID-19.
In the cooperation between Achiko and Indofarma, a member of Indonesia’s Holding BUMN Farmasi, which is partly owned by the Government of the Republic of Indonesia and listed on the Indonesia Stock Exchange (IDX: INAF), Achiko will provide the technology and all materials for diagnostic kits while Indofarma will carry out the production and product registration processes.
Following the Ministry of Health’s approval for AptameX™, Achiko is looking forward to securing a CE mark and introducing AptameX™ and Teman Sehat™ swiftly in further countries and regions. In parallel, Achiko is also investigating applications of AptameX™ to a range of other pathogenic diseases and therapeutic indications.
Achiko, on product approval, has raised a total amount of CHF 3.45 million through share placement at an average price of CHF 0.192 per share to a leading Swiss venture capital group, OCS International Commodities & Investments FZCO, and other private investors. The funds are to be used as working capital and production funds as well as for the redemption of the Yorkville convertible note facility from 25 November 2020.
Request information using button provided below, or visit achiko.com to learn more.
Date Published: 13th September 2021
Source article link: View
Note: This content has been edited by a rapidvirology.com staff writer for style and content.
Life-on-Mars Project Selects Airborne Particle
Self-Collection Patient-Friendly Swab is CE-marked